Company Profile

sterna biologicals is a privately held, clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis.

By targeting GATA-3, a key transcription factor that plays a central role in dysregulated type-2 inflammation driven chronic diseases, the company’s proprietary DNAzyme-based drug candidate hgd40 broadly antagonizes several inflammatory processes and mediators at the same time - opposite to many existing treatments that only address specific individual inflammatory mediators.